PUBLISHER: The Insight Partners | PRODUCT CODE: 1997060
PUBLISHER: The Insight Partners | PRODUCT CODE: 1997060
The Brachytherapy Devices Market size was valued at US$1.04 billion in 2025 and is expected to reach US$1.93 billion by 2034. The brachytherapy devices market is estimated to register a CAGR of 7.2% during 2026-2034.
The growing preference for minimally invasive cancer treatments is a major driver of the global brachytherapy devices market. Cancer, once widely viewed as a life-threatening condition with limited treatment options, is increasingly becoming manageable due to advances in medical technology. Among these advances, minimally invasive treatment approaches have gained strong acceptance from both patients and healthcare providers because they reduce physical trauma, shorten recovery times, and improve overall quality of life.
Minimally invasive procedures are characterized by smaller incisions, targeted treatment delivery, reduced pain, and lower risk of complications compared to conventional open surgeries. These benefits are particularly important in cancer care, where patients often undergo multiple treatments and require faster recovery to maintain daily functioning. Brachytherapy aligns closely with this preference, as it delivers radiation directly to the tumor site with minimal impact on surrounding healthy tissues, often without the need for extensive surgery.
The rising global cancer burden further reinforces this shift. As of June 2023, the World Health Organization (WHO) reported that lung cancer alone accounts for nearly 1.8 million deaths annually, highlighting the urgent need for effective and patient-friendly treatment options. With cancer cases continuing to rise, healthcare systems are increasingly prioritizing treatments that are both clinically effective and less invasive.
Cancer centers worldwide are responding by investing in advanced minimally invasive technologies. Institutions such as Vydehi Cancer Center emphasize precision-driven cancer care through minimally invasive techniques, supported by modern infrastructure and specialized clinical expertise. This growing focus on targeted, patient-centric treatment approaches is significantly driving demand for brachytherapy devices, supporting their continued adoption in modern oncology care.
The North America Brachytherapy Devices Market shows consistent growth, supported by a well-developed healthcare system, high cancer incidence, and strong adoption of advanced radiation therapy technologies. The region benefits from the presence of specialized cancer treatment centers, favorable reimbursement frameworks, and continuous investment in oncology research and development. Brachytherapy is widely adopted due to its precision, shorter treatment cycles, and ability to minimize radiation exposure to surrounding healthy tissues.
The United States holds the largest share of the North American market, driven by early adoption of innovative medical technologies and the presence of leading device manufacturers and distributors. Canada also contributes steadily through increasing access to modern cancer care and government-supported healthcare initiatives. High-dose-rate (HDR) brachytherapy systems, radioactive seeds, and image-guided treatment solutions remain key areas of technological advancement across the region.
Industry consolidation and strategic partnerships play an important role in shaping the competitive landscape. In January 2021, BEBIG Medical GmbH assumed global production and distribution of HDR brachytherapy products previously managed by Eckert & Ziegler BEBIG GmbH, including Mick Radio-Nuclear Instruments, Inc. This development strengthened supply chain efficiency and product availability, benefiting healthcare providers in North America. Additionally, in May 2024, GT Medical Technologies partnered with Theragenics Corporation to expand physician access to Cesium-131 brachytherapy seeds. Under the agreement, Theragenics became the exclusive distributor of Cesium-131 seeds and carriers for multiple non-brain cancer treatments, including prostate cancer, supporting wider clinical adoption.
Overall, ongoing technological innovation, strong distribution networks, and increasing focus on precision oncology are expected to sustain growth in the North American brachytherapy devices market, reinforcing its position as a key region for advanced internal radiotherapy solutions.
Eckert & Ziegler AG; Elekta AB; Siemens Healthineers AG; Becton Dickinson and Co; Theragenics Corporation; BEBIG Medical; Carl Zeiss Meditec; CIVCO Medical Solutions; GE HealthCare Technologies Inc; and C4 Imaging are among the key brachytherapy devices market players that are profiled in this market study.
The overall brachytherapy devices market size has been derived using both primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the brachytherapy devices market size. The process also helps obtain an overview and forecast of the market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain analytical insights. This process includes industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the EMEA brachytherapy devices market.